Article
Oncology
Uros Bumbasirevic, Marko Zivkovic, Milos Petrovic, Vesna Coric, Nikola Lisicic, Nebojsa Bojanic
Summary: In the treatment of seminoma, routine radiotherapy is no longer recommended for clinical stage I patients. Instead, a risk-adapted approach is preferred, with adjuvant carboplatin chemotherapy as the main treatment option. Active surveillance can prevent overtreatment but requires strict follow-up and increased radiation exposure.
Article
Oncology
Bela Mrinakova, Karol Kajo, Viera Lehotska, Martina Ondrusova, Sona Balogova, Zuzana Pinakova, Vera Novotna, Vanda Usakova, Lucia Fedorkova, Iveta Waczulikova, Juraj Kausitz, Dalibor Ondrus
Summary: This study compared the impact of active surveillance (S) and adjuvant chemotherapy (ACT) on the survival of patients with clinical stage I testicular seminoma. The results suggest that for high-risk patients, ACT may be a suitable treatment, while S is a viable option for low-risk patients.
Article
Oncology
J. Aparicio, X. Garcia del Muro, P. Maroto, J. Terrasa, D. Castellano, R. Bastus, J. Guma, N. Sagastibeltza, I Duran, S. Ochenduszko, J. A. Meana, J. Garcia-Sanchez, J. A. Arranz, R. Girones, J. R. Germa
Summary: In the context of risk-adapted treatment for stage I seminoma, administering two courses of AC to patients with tumor size > 4 cm and/or rete testis invasion is associated with a higher incidence of second recurrences but does not significantly modify the pattern of relapses or their outcome.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Goncagul Akdag, Ozkan Alan, Akif Dogan, Zeynep Yuksel, Sedat Yildirim, Oguzcan Kinikoglu, Emre Kudu, Heves Surmeli, Hatice Odabas, Mahmut Emre Yildirim, Nedim Turan
Summary: This study aimed to investigate the effects of treatment options on the prognosis of stage-I testicular seminoma patients. The results showed that adjuvant therapy did not significantly improve disease-free survival compared to active surveillance. Furthermore, lymphovascular invasion was identified as an important prognostic indicator for determining the treatment strategy and prognosis.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Mitchell M. Huang, Zhuo T. Su, Joseph G. Cheaib, Michael J. Biles, Mohamad E. Allaf, Hiten D. Patel, Phillip M. Pierorazio
Summary: The study shows that non-risk-adapted active surveillance (NRAS) is the most cost-effective management strategy for patients with clinical stage I (CSI) seminoma, offering the lowest per-patient healthcare cost and highest Quality-Adjusted Life Years (QALYs) gained over a 10-year period. NRAS also allows a high percentage of patients to avoid unnecessary treatment compared to current practice and risk-adapted active surveillance.
EUROPEAN UROLOGY FOCUS
(2021)
Review
Medicine, General & Internal
Dong Hyuk Kang, Kang Su Cho, Jae Yong Jeong, Young Joon Moon, Doo Yong Chung, Hae Do Jung, Joo Yong Lee
Summary: This study suggests that there is no significant difference in overall survival between active surveillance (AS) and adjuvant treatment for patients of CSI seminoma within 5 years, but adjuvant treatment reduces the risk of recurrence within 5 years.
MEDICINA-LITHUANIA
(2022)
Article
Medicine, General & Internal
Sijian Li, Xinyue Zhang, Tianyu Zhang, Min Yin, Dongyan Cao, Yang Xiang, Jiaxin Yang
Summary: The prognostic factors for POIT include positive postoperative tumor markers and FIGO stage II-IV. Active surveillance may be practical for patients with negative postoperative tumor markers in stage I POIT.
ANNALS OF MEDICINE
(2023)
Review
Urology & Nephrology
Julian Chavarriaga, Adam Bobrowski, Robert J. Hamilton
Summary: This article reviews and compares international guidelines and surveillance protocols for the diagnosis, management, and follow-up of clinical stage 1 (CS1) testicular cancer. The authors analyzed 46 articles on proposed follow-up strategies and six clinical practice guidelines, finding considerable variability and differences in recommended follow-up intensity.
Article
Oncology
Shi Jia, Jingping Qiu
Summary: In the United States, the proportion of patients with stage I seminoma receiving radiotherapy has gradually decreased over the past 40 years, with active surveillance and chemotherapy becoming alternative strategies. Younger and married patients are more likely to avoid radiotherapy. Patient overall survival decreased in the early 2000s, but showed no significant difference in survival rates between 2008-2015 and 1975-1999.
TRANSLATIONAL CANCER RESEARCH
(2021)
Review
Urology & Nephrology
Jerusha Padayachee, Roderick Clark, Padraig Warde, Robert J. Hamilton
Summary: Testicular cancer is the most common solid malignancy among young men. Active surveillance following radical orchiectomy is preferred for stage I disease to maintain excellent survival outcomes while minimizing the toxicity of adjuvant treatment.
CURRENT OPINION IN UROLOGY
(2022)
Review
Urology & Nephrology
Muhannad Alsyouf, Siamak Daneshmand
Summary: Testicular germ cell tumors (GCTs) are the most common malignancy among young males. The majority of patients present with early stages of the disease that are highly curable. Primary retroperitoneal lymph node dissection (RPLND) has been shown to be effective for low-volume metastatic GCT, providing an alternative to systemic chemotherapy.
EUROPEAN UROLOGY FOCUS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Rishi Narine, Heba Osman, Sirote Wongwaisayawan, Scott Morgan, Luke T. Lavallee, Nicola Schieda
Summary: Unenhanced MRI was found to be adequate for surveillance of stage 1 testicular cancer, but radiologist inexperience may lead to errors. The study also showed substantial inter-observer agreement among radiologists.
ABDOMINAL RADIOLOGY
(2021)
Article
Oncology
Alexandros Papachristofilou, Jens Bedke, Stefanie Hayoz, Ulrich Schratzenstaller, Miklos Pless, Marcus Hentrich, Susanne Krege, Anja Lorch, Daniel -M Aebersold, Paul Martin Putora, Dominik-R Berthold, Deborah Zihler, Friedemann Zengerling, Annette Dieing, Arndt -Christian Mueller, Corinne Schaer, Christine Biaggi, Silke Gillessen, Richard Cathomas
Summary: A novel approach combining de-escalated chemotherapy with de-escalated involved node radiotherapy resulted in a 3-year progression-free survival rate of 93.7% with minimal toxic effects. The primary endpoint was not met, but the findings suggest that this regimen could be an alternative to standard-of-care treatment. Further research is needed to confirm these results.
Article
Oncology
Emily Butts, Denise Gococo-Benore, Tanmayi Pai, Muhamad Alhaj Moustafa, Fei Heng, Ruqin Chen, Yujie Zhao, Rami Manochakian, Yanyan Lou
Summary: The objective of this study is to assess the pattern of recurrence and development of second primary lung cancer in patients with stage I non-small cell lung cancer following curative therapy. It was found that negative tobacco history and stage IA tumors were associated with prolonged disease-free survival, while tobacco history and stage IB were risk factors for recurrence. An individualized approach based on risk factors should be taken into consideration when deciding to continue CT surveillance after five years post curative therapy for stage I NSCLC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Urology & Nephrology
Maximilian Peter Brandt, C. Ruf, K. P. Dieckmann, I Syring, C. Ruckes, T. Nestler, H. U. Schmelz, R. Dotzauer, A. Hiester, P. Albers, D. Nettersheim, C. Bolenz, S. H. Loosen, A. Heidenreich, D. Pfister, A. Haferkamp, F. Zengerling, P. Paffenholz
Summary: In this study, the clinical characteristics and oncological outcomes of patients with CSIS were assessed. Data from five tertiary referring centers in Germany were analyzed, identifying 43 out of 2616 TGCT patients as CSIS. The correct classification of cCSIS was crucial in guiding treatment and achieving a 5-year relapse-free survival rate of 88.9%.
WORLD JOURNAL OF UROLOGY
(2022)
Review
Oncology
Grace Kusi, Eshetu G. Atenafu, Adwoa Bemah Boamah Mensah, Charlotte T. Lee, Auro Viswabandya, Martine Puts, Samantha Mayo
Summary: Psychoeducational intervention (PEI) has a positive effect on cancer caregivers, reducing caregiver burden, improving quality of life, and reducing anxiety and depression. The study also found that intervention characteristics such as studies conducted in high-income countries, group interventions, and studies focused on specific and mixed cancers can impact the effectiveness of the intervention.
Letter
Hematology
Marta Davidson, Florence Wong, Mostafa Atri, Hassan Sibai, Dawn Maze, Verna Cheung, Jeannie Callum, Eshetu G. Atenafu, Vikas Gupta
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biophysics
Maria Queralt Salas, Eshetu G. G. Atenafu, Ivan Pasic, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Arjun Datt Law, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Kim, Armin Gerbitz, Auro Viswabandya, Fotios V. V. Michelis, Jeffrey Howard Lipton, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar
Summary: This study designs an HCT Frailty Scale to classify alloHCT candidates into different frailty groups, which can be implemented in the first consultation without additional cost. The scale uses eight variables to assess and calculate the frailty score of a patient, which can predict the one-year overall survival rate. The scale is a low-cost and highly informative prognostic signal for outcomes at the pre-transplant stage.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Sahar Khan, Donna Reece, Eshetu G. Atenafu, Sita Bhella, Christine Chen, Esther Masih-Khan, Harminder Paul, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti
Summary: A retrospective evaluation was conducted on 106 multiple myeloma patients who underwent upfront therapy with PI based induction and ASCT (+/- IMiD maintenance) to assess the outcome of salvage ASCT. At a median follow-up of 26 months, the estimated median PFS and OS were 24 and 80 months respectively. PFS post ASCT1 of at least 42 months and IMiD non-refractory disease were associated with improved outcome.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Davidson Zhao, Entsar Eladl, Mojgan Zarif, Jose-Mario Capo-Chichi, Andre Schuh, Eshetu Atenafu, Mark Minden, Hong Chang
Summary: This study retrospectively evaluated 266 AML-MRC patients and found that TP53(MUT) AML-MRC is a very-high-risk subtype of AML with poor prognosis. Patients with high TP53(MUT) variant allele frequency had worse outcomes. TP53 mutations and elevated serum LDH were independent predictors for inferior prognosis.
Article
Hematology
Samantha A. Hershenfeld, Eshetu G. Atenafu, Steven Chan, Vikas Gupta, Dawn Maze, Andre Schuh, Hassan Sibai, Karen Yee, Aaron Schimmer
Summary: This study found that distance from the treatment center did not significantly affect the choice of upfront therapy, participation in clinical trials, or clinical outcomes for patients with acute myeloid leukemia (AML) in Ontario's single payer healthcare system.
ACTA HAEMATOLOGICA
(2023)
Article
Oncology
P. L. Jorgensen, M. Kreiberg, N. Jorgensen, A. Juul, P. S. Oturai, C. Dehlendorff, J. Lauritsen, T. Wagner, J. Rosenvilde, G. Daugaard, C. R. Medici, N. R. Jorgensen, M. Bandak
Summary: The aim of this study was to evaluate the metabolic profile and bone mineral density (BMD) changes in testicular cancer survivors with mild Leydig cell insufficiency after 12 months of testosterone replacement therapy (TRT). The results showed that TRT did not significantly affect BMD, but it resulted in a small increase in N-terminal propeptide of type 1 procollagen (P1NP), which had little clinical significance.
Article
Hematology
James T. T. England, Eshetu G. G. Atenafu, James A. A. Kennedy, Burhan Goraya, Verna Cheung, Taylor Nye, Karine Gauthier, Marta B. B. Davidson, Aniket Bankar, Hassan Sibai, Dawn Maze, Auro Viswabandya, Vikas Gupta
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
RuiQi Chen, Eshetu G. Atenafu, Jack Seki, Xing Liu, Steven Chan, Vikas Gupta, Dawn Maze, Andre C. Shuh, Mark D. Minden, Karen Yee, Aaron D. Schimmer, Hassan Sibai
Summary: This study found that PEG-ASP is associated with a higher incidence of VTE compared to L-ASP in patients with ALL, despite prophylactic anticoagulation. Further VTE mitigation strategies are needed for adult patients receiving PEG-ASP.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Jawad M. Melhem, Ali Tahir, Eirena Calabrese, Inga Granovskaya, Eshetu G. Atenafu, Arjun Sahgal, Mary Jane Lim-Fat, James R. Perry
Summary: This study aimed to validate the safety and efficacy of low-dose bevacizumab (BEV) for patients with recurrent glioblastoma (rGBM). The study found that compared to the standard dose regimen, low-dose BEV was associated with significantly prolonged overall survival and progression-free survival. Lower dose schedules may be a better and more cost-effective option, providing more equitable access to the palliative drug.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Clinical Neurology
Daniel Moore-Palhares, Arjun Sahgal, K. Liang Zeng, Sten Myrehaug, Chia-Lin Tseng, Jay Detsky, Hanbo Chen, Mark Ruschin, Eshetu G. Atenafu, Jeff Wilson, Jeremie Larouche, Leodante da Costa, Pejman Jabehdar Maralani, Hany Soliman
Summary: This study reports the outcomes of a novel fractionation scheme, 30 Gy in 4 fractions, for the treatment of spinal metastases. The results show that this approach is safe and effective, especially for patients with a clinical target volume (CTV) volume of ≥72 cc.
Article
Multidisciplinary Sciences
Samantha Tam, Rajat Kumar, Paty Lopez, Jonas Mattsson, Shabbir Alibhai, Eshetu G. Atenafu, Lori J. Bernstein, Eugene Chang, Susan Clarke, David Langelier, Jeffrey Lipton, Samantha Mayo, Tina Papadakos, Jennifer Michelle Jones
Summary: This study aims to develop a 6-month rehabilitation program for patients undergoing alloBMT and test the feasibility and acceptability of the program through a randomized controlled trial. It will also collect secondary clinical outcomes to inform future research.
Article
Oncology
Davidson Zhao, Mojgan Zarif, Qianghua Zhou, Jose-Mario Capo-Chichi, Andre Schuh, Mark D. Minden, Eshetu G. Atenafu, Rajat Kumar, Hong Chang
Summary: TP53 mutations are adverse-risk genetic aberrations in acute myeloid leukemia (AML). The optimal treatment approach for patients with TP53-mutated (TP53(MUT)) AML remains unclear. This study aimed to evaluate the prognostic implications of different frontline treatment strategies and transplantation for patients with TP53(MUT) AML. The results suggest that current therapeutic strategies are ineffective for TP53(MUT) AML patients, highlighting the urgent need for new treatment strategies for this high-risk population.
Article
Oncology
Nazanin Aghel, Dakota Gustafson, Diego Delgado, Eshetu G. Atenafu, Jason E. Fish, Jeffrey H. Lipton
Summary: Tyrosine kinase inhibitors (TKIs) have had a significant impact on the treatment of chronic myelogenous leukemia (CML), but they may have cardiovascular toxicities. This study examined the relationship between the marker hsCRP and vascular dysfunction markers with exposure to specific TKIs in CML patients. The results showed that hsCRP levels were not associated with disease activity or treatment with specific TKIs, but other markers of vascular dysfunction were altered in patients treated with certain TKIs.
LEUKEMIA & LYMPHOMA
(2023)
Article
Rheumatology
Sonya T. Kim, Carolina Munoz-Grajales, Shannon E. Dunn, Raphael Schneider, Sindhu R. Johnson, Zahi Touma, Zareen Ahmad, Dennisse Bonilla, Eshetu G. Atenafu, Linda T. Hiraki, Arthur Bookman, Joan Wither
Summary: It has been found that measuring the levels of IFN-alpha in serum can accurately predict the immune-induced gene expression in ANA(+) individuals and be used for clinical prediction. At the same time, measuring the levels of CXCL-10 and Galectin-9 can also predict the progression of the disease in ANA(+) individuals.
ARTHRITIS RESEARCH & THERAPY
(2023)